Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Interferon beta-1a overdose in a multiple sclerosis patient.

Nicola P Falcone1, Agostino Nappo, Berend Neuteboom

  • 1Unità Operativa di Neurologia, Ospedale Belcolle, Viterbo, Italy. nicfalc@libero.it

The Annals of Pharmacotherapy
|October 6, 2005
PubMed
Summary

A patient with multiple sclerosis (MS) overdosed on interferon (IFN) beta-1a in a suicide attempt. The overdose caused only temporary symptoms, suggesting IFN beta-1a therapy is safe even at high doses.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction to: Anakinra in Creutzfeldt-Jakob disease.

Acta neurologica Belgica·2022
Same author

Anakinra in Creutzfeldt-Jakob disease.

Acta neurologica Belgica·2022
Same author

Avelumab internalization by human circulating immune cells is mediated by both Fc gamma receptor and PD-L1 binding.

Oncoimmunology·2021
Same author

Changing Body Weight-Based Dosing to a Flat Dose for Avelumab in Metastatic Merkel Cell and Advanced Urothelial Carcinoma.

Clinical pharmacology and therapeutics·2019
Same author

Time-Varying Clearance and Impact of Disease State on the Pharmacokinetics of Avelumab in Merkel Cell Carcinoma and Urothelial Carcinoma.

CPT: pharmacometrics & systems pharmacology·2019
Same author

Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial.

The Lancet. Oncology·2017

Area of Science:

  • Neuroimmunology
  • Clinical Pharmacology

Background:

  • Multiple sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system.
  • Depression is a common comorbidity in MS patients, impacting treatment adherence and quality of life.

Observation:

  • A 38-year-old male MS patient with depressive symptoms self-administered a large overdose of subcutaneous interferon (IFN) beta-1a (approximately 264-308 mug).
  • The patient presented with transient symptoms including mild fever and skin redness, which resolved within 24 hours.
  • Laboratory tests revealed no significant biochemical or hematologic changes.

Findings:

  • The patient's depressive symptoms were attributed to the discontinuation of citalopram, an antidepressant, rather than IFN beta-1a therapy.
  • High-dose IFN beta-1a exposure resulted in only self-limiting malaise, indicating a wide safety margin.

Related Experiment Videos

Implications:

  • This case underscores the critical importance of managing depression in MS patients and the risks associated with discontinuing antidepressant treatment.
  • It demonstrates the safety profile of IFN beta-1a, even at supratherapeutic doses, in MS patients.